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2Abstract
Optimization of biological performance of a carrier in cancer drug delivery depends on the 
targeting potential of the delivery system and its ability to control the drug release precisely. 
Dendrimers has emerged as a potential carrier of anticancer drugs due to some unique properties 
such as mono-dispersity, defined structure, amenability for functionalization using diverse 
ligands and its low-nanometer size. The dendrimers could be decorated to make them smart 
enough to carry the drug to the desired locus and release it in a controlled manner. The 
introduction of stimuli responsive functionality on dendrimers allows the release of payloads in 
response to a specific trigger only. These triggers could be endogenous in nature (acid, enzyme, 
and redox potentials) or it could be applied externally (light and temperature). These smart 
functionalities synergize the targeting of dendrimers and enable dendrimer-based anticancer drug 
delivery more efficient and safer. This review highlights the potential of stimuli responsive 
strategy for the controlled release of anticancer drug from dendritic assemblies. 
 Keywords: Dendrimers; Drug release; Cancer; Drug targeting; Toxicity; Anticancer drug  
31. Introduction
Optimizing the outcome of already existing drugs is currently the focusing area of 
research in view of improving physicochemical, biodistribution and pharmacokinetic properties 
of the drugs to enhance therapeutic benefit with minimal side-effects. The size manipulation at 
the molecular level could leads to new intrinsic properties and would be translated as 
technological innovations for improving the outcome of conventional systems. In field of 
medicine such technological innovations are termed as nanomedicine. The aim of nanomedicine 
is to diagnose a disease in its initial stage and to treat it rapidly and specifically, therefore, 
restrict long-term damage [1]. The field of nanomedicine could be prudently utilized in the 
management of the world’s most deadly disease cancer which is responsible for about 22% of all 
human deaths annually from non-communicable diseases [2,3]. 
With hundreds of signaling pathways and multiple causes that respond differently to 
various treatments, cancer remains an ongoing challenge with enormous health and financial 
burdens on patients and society. The stage of the cancer is the decisive factor in opting the 
treatment regimen via surgery, radiation, chemotherapy, biological and hormone therapy. 
Nonetheless, chemotherapy remains the mainstay option for cancer management and depending 
on type of cancer and its advancement, it is used as adjuvant with surgery, radiation therapy, or 
biological therapy [4].
Non-selective biodistribution, low aqueous solubility with poor membrane permeability 
and rapid clearance, hypersensitivity reactions, and advent of multidrug resistance (MDR) are the 
major challenges in conventional chemotherapy [5]. Thus, a drug therapy that shows 
reproducibility in pharmacokinetic behavior and is target specific is sought. A stable, 
monodisperse, well-defined system could ensure the reproducibility in pharmacokinetic behavior 
4of a therapy in-vivo. This realization leads to the synthesis of hyperbranched polymers termed as 
dendrimers [6]. 
2. Dendrimers: An outline
Dendrimers, a class of artificial macromolecules, are nanosize, monodisperse, multivalent 
polymeric systems with well-defined structure. These unique exciting features ensure a pivotal 
role of dendrimers in the management of cancer. Structurally, a dendrimer has a treelike 
molecular construction and comprises of three main architectural components including a core, 
branching layers (termed as generations) consist of repeating units surrounding the internal core 
and a multivalent external surface. Generation number (G) signifies the number of focal points 
from the core towards the surface and is used to determine molecular weight and the number of 
terminal functional groups [7]. Drugs could either be encapsulated within dendrimers internal 
cavity or bound to their surfaces through hydrophobic, electrostatic or covalent interactions. The 
immense potential in this class of molecular construct leads to synthesis of various classes of 
dendrimers, such as poly(propylene imine) (PPI), poly(amidoamine) (PAMAM), chiral, 
amphiphilic, micellar, Tecto, Frechet and Janus dendrimers and are also commercially available 
[8].
Due to highly dense structure, perfect chemical definition and a well-defined number of 
surface functionalities, dendrimers could be adaptable to multifunctional modifications with 
valuable flexibility for grafting different chemical moieties on the surface, at the core, or within 
the structure. The most promising feature of dendrimers is their multi-valency, which presents 
multiple arrays of ligands to the target bearing multiple receptors. This leads to a greatly 
increased interface between the dendrimer and the target enhancing affinity and activity [9,10].
2.1 Comparative account of linear polymer, dendritic polymers and dendrimer
5Dendritic polymers considered as branched polymeric architectures, are classified into 
random hyperbranched polymers, dendrigraft polymers, dendrons, and dendrimers based on 
degree of structural control [11]. In general, branched polymers have sophisticated topological 
structures and exciting physico-chemical and biological properties. In comparison to their linear 
analogues, branched polymers have three-dimensional globular structure, lower solution/ melting 
viscosity, smaller hydrodynamic radius, higher degree of functionality, increased encapsulation 
capabilities, enhanced solubility and minimal molecular entanglement. Owing to high 
functionality, dendritic structures, allows dense incorporation of drugs, imaging and targeting 
agents [12]. Monodisperse nature of dendrimers, in addition, provides reproducible 
pharmacokinetic behavior as compared to linear polymers, which are generally polydisperse and 
thus containing varying molecular weighed fractions among a given sample. Also, controlled 
globular shape of dendrimers other than entangled and coiled structures of linear polymers 
enhances their biological properties [13]. Furthermore, prospect of surface engineering due their 
high density of functionalities allow to tune their thermal, mechanical, rheological, solution 
properties (size, conformation, solubility), and biocompatibility. These features can further 
improve the biodistribution and pharmacokinetic profile, tendency of crossing biological 
barriers, blood circulation time and tumor penetration [14-16].
2.2 Toxicologial profile of dendrimers and remedies
The emergence of dendrimers is foresighted as solution to various biomedical difficulties 
due to distinct features like nanometric size, well-defined structure, narrow polydispersity and 
large number of surface groups. However, owing their toxic potential including hemolytic 
toxicity, cytotoxicity, immunogenicity and in vivo toxicity, the credentials of their clinical 
applications is limited. The toxicity of dendrimers is related to surface charge, generation and 
6size [17, 18]. Various approaches are being utilized to improve the therapeutic index of 
dendrimers including development of biodegradable and/or biocompatible, surface engineered 
dendrimers and use of dual drug delivery systems. The biodegradable dendrimers, generally 
composed by biodegradable repeat units that will eliminate metabolic pathways and thus will not 
accumulate, therefore considered as non-toxic [19]. Surface engineering masks the cationic 
charge of dendrimer surface either by neutralization of charge, for example PEGylation, 
acetylation, carbohydrate and peptide conjugation; or by introducing negative charge on the 
surface of dendrimers [10]. Dendrimer based hybrid nanocarrier is recognized as a recent 
approach to minimize the toxicity, improving dispersibility, biocompatibility, payloads and 
pharmacokinetics of dendrimers as compared to other carriers such as liposomes, nanoparticles, 
quantum-dots, carbon nanotubes and microsphere [20].
2.3 Dendrimer based drug targeting approach 
Dendrimers has emerged as unique polymeric globular nanoparticulate drug delivery system that 
could be judiciously utilized to tackle the deadliest disease cancer. The inimitable topographical 
molecular architect encompassing this class of delivery system could allow the delivery of 
varying nature of anticancer bioactives viz lipophilic or hydrophilic drugs and macromolecules 
as proteins or RNA. The prospect of multifunctionality owing to multivalency, leads to 
decoration of their surface by different moieties for varying function to achieve a common goal 
and this could significantly enhance the efficacy of the transported bioactives. The conventional 
chemotherapy for cancer management exhibits a lack of selectivity and thus affecting healthy 
tissues. To realize selectivity, the dendrimers could be functionalized using moieties that would 
synergistically act to target the tumoral cells and release the payloads at the desired site. The 
approach of “cellular or secondary targeting” based on moieties that leads to ligand–receptor-
7mediated endocytosis or of “tertiary targeting” based on moieties that recognize internal 
organelles or the use of stimuli-responsive moieties that are responsible for release of bioactives 
under specific internal or external stimuli, in combination onto a single dendritic structure 
synergistically act to achieve selective targeting [3,9,20].
3. Dendrimer-based multifunctional theranostics for cancer treatment
The unique features encompassing dendrimers enable their utilization for varied 
biomedical applications. Early prognosis of the fundamental molecular processes that cause 
cancer is anticipated from modern imaging technologies. However, the conventionally used 
contrast agents suffer with short imaging time, renal toxicity and lack of specificity. Dendrimers 
are now being explored as a platform for surface conjugation of various contrast agents including 
fluorescent dyes, iodinated contrast agents, and gadolinium (Gd) or radionuclide chelators and 
for entrapment, stabilization, or assembly of metal (e.g., Au), metal sulfides, and magnetic iron 
oxide NPs, leading to the formation of a range of contrast agents for different techniques 
including single mode fluorescence, computed tomography (CT), magnetic resonance (MR), 
positron emission tomography (PET), and single photon emission computed tomography 
(SPECT), and dual mode MR/CT, MR/fluorescence, PET/fluorescence, and 
SPECT/fluorescence. Further, the scope of incorporation of drug into ligand attached dendrimer-
based contrast agents could pave the path to design dendrimer-based multifunctional theranostic 
agents for specific diagnosis and therapy of cancer [21-24]. 
Though, chemotherapy is currently considered to be the mainstream therapy for cancer 
management, however due to lack of selective targeting, it would affect healthy cells along with 
cancerous cells. Tumor physiology allows passive tumor targeting of drug-dendrimer conjugate 
by enhanced permeability and retention (EPR) effect [25]. In addition to this, molecularly active 
8targeted delivery of anticancer drugs on specific molecular target, could be achieved by surface 
functionalization of the dendrimer using various targeting moieties [26]. However, despite 
considerable efforts towards drug targeting, optimum outcome has not been observed and this 
may be due to a poor drug internalization and/or inefficient release of drug intracellularly. 
Efficient therapeutic strategy that could improve targeting and control drug release is currently 
the area of research in oncology domain. Thus, an efficient targeted drug delivery system should 
not only be able to achieve preferential accumulation and selective binding to the targeted cells 
but also been able to endorse cellular internalization, endosomal escape and control drug release 
[27, 28]. 
In view of the above, along with targeting ligand, dendritic system encompasses stimuli-
responsive controlled release function that is responsive under specific internal or external 
stimuli. Alike the feasibility of passive targeting to tumor due to EPR effect, the release of the 
drug at target site could be controlled by exploiting the differential conditions existed at tumor 
microenvironment. Presence of biochemical gradient between tumor tissue and normal 
physiological tissue such as pH, redox potential, and enzymes can be exploited as internal stimuli 
for controlling the release of drugs. Among the external stimuli, use of feature that are 
responsive to temperature and light are attached onto dendrimers to create externally triggerable 
systems [29, 30]. 
Low pH at the extracellular space of solid tumors due to excessive accumulation of lactic 
acid and lower pH of some intracellular compartments such as the endosomes and lysosomes has 
driven interest in pH responsive assemblies for cancer therapy. Likewise, interest in redox 
sensitive carrier develops due to differences in the redox potential between extracellular space 
and the cytoplasm due to accumulation of reactive oxygen species (ROS) in cancer tissue. 
9Further, overexpression of various enzymes is observed in cancerous tissue due to augmented 
metabolic processes and thus could be used for designing enzyme responsive assemblies. 
Though, the utilization of external stimuli responsive assemblies like light and temperature 
responsive moieties are being researched for cancer drug delivery, however their utilization is 
associated with concerns regarding safety and penetration depth [31, 32].
The use of stimuli responsive smart linkers between drug and dendrimer is commonly 
utilized to control the release of free drug from drug-linker-dendrimer conjugate. The release of 
the drug in response to the stimuli is due to either reversible and irreversible transformations in 
the conjugate. However most of the stimuli leads to irreversible cleavage of the linkers. 
However, the stability and liability of the bond between the dendrimer, linker and drug under 
physiological conditions and in tumor tissue respectively governs the release behavior of the 
drug from drug dendrimer conjugate [33].
In addition to this, self-assembled dendritic systems that could disassembled in response 
to stimuli could also be employed to control dug release. Noncovalent interactions such as 
hydrogen bonding, π-π stacking and hydrophobic interactions are involved in self-assembly of 
dendritic systems [34]. The stability and nature of the aggregates are dependent on hydrophilic-
hydrophobic proportion, and on external conditions  such  as  temperature and concentration [35, 
36].
Further, the class of self-immolative dendrimers is employed to control drug release 
which upon exposure to a specific trigger allow continuous degradation of their structure into 
small molecules [37]. In design, self-immolative dendrimers consists of a triggering unit 
connected to the branched skeleton composed of adaptor units. The adapter units are further 
attached with drugs as tail units. For controlled release of drugs, stimulation of trigger unit, 
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initiates rapid disassembly of the branched skeleton, with the subsequent release of all tail-units. 
“Dendritic amplification” or “Cascade-release” are the term used synonymously for the 
triggering response that leads to degradation of the conjugate [38-40]. Further, different self-
immolative bonds can be used to adjust the degradation rate of the conjugate [41].
This review highlights various stimuli responsive dendritic assemblies utilized for the 
delivery of anticancer drugs. Different types of internal and external stimuli including acid, 
reduction potential, enzyme, temperature and light are discussed along with the respective 
responsive linkers that trigger the release in response to stimuli. 
4. pH responsive dendrimers 
The existence of pH gradient between tumor microenvironment (pH ~6.5) and normal 
tissues (pH ~7.4) act as a trigger for the controlled release of payloads from the drug delivery 
systems. An acid responsive functionality is anchored with such delivery devices, which remains 
stable in neutral and alkaline environment but gets degraded or hydrolyzed on exposure to acidic 
environment to release the drug. Further, some intracellular compartments, such as the 
endosomes and lysosomes have an acidic pH profile (4.5–6.5) that could trigger cytoplasmic 
drug release from acidic endo-lysosomal compartments [42]. 
Rapid proliferation effect in tumor tissues results in enhanced glycolysis instead of 
oxidative phosphorylation resulting in excessive accumulation of lactic acid and this will lead to 
slight decrease in pH of tumor extracellular environment. This decrease in pH is first observed 
by Warburg and is termed as Warburg effect [43, 44]. 
Presence of ionizable functional groups such as amine and carboxylic acid on surface or 
inner of dendrimer exhibit a pH-dependent release due to disruption of amphiphilicity of the 
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system. For example, low pH leads to protonation of tertiary amine which decreases the interior 
hydrophobicity of dendrimer and facilitate the release of payloads at the tumor site [45-47]. 
The pH gradient, also driven disassembly of assemble structure of amphiphilic 
dendrimers and thus aid in controlling release of payloads. Under specific pH conditions 
amphiphilic dendrimers assembled into micelles and these assembled structures tend to 
disassemble with altered conformation due to pH driven alteration in hydrophilic-lipophilic 
balance (HLB) [48, 49].
4.1 pH responsive linkers
The use of acid labile linkers could also be utilized in the construction of pH sensitive 
dendrimer. The acid labile linkers respond to variation in pH, they remain stable in neutral or 
alkaline pH, but degraded or hydrolyzed at acidic pH. Among pH-responsive linkers, the most 
frequently employed for anticancer drug delivery via dendrimer drug conjugate are hydrazone, 
acetal, and cis-acotinyl (Table 1) [42, 50].
4.1.1 Hydrazone linkage
Hydrazone linkages are most commonly used pH responsive linkage for designing 
dendrimer-prodrugs for cancer therapy. The hydrazone linkages hydrolyzed under acidic 
conditions and remain stable at neutral and alkaline pH [51]. The most common synthetic 
pathway for hydrazone is the condensation between hydrazines and ketones or aldehydes. 
Though hydrazones could also be synthesized by reaction between aryl halides and non-
substituted hydrazones, and by reaction between aryl diazonium salts and beta-keto esters or 
acids (Japp-Klingemann reaction) [52].
A ketone or aldehyde group is required for hydrazone formation and thus hydrazine 
linkage is common with Doxorubicin (DOX)-dendrimer prodrug (Figure 1). Antitumor drugs, 
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without this functional group requires additional modification for conjugation via hydrazone 
bond. Drugs bearing hydroxyl group such as Paclitaxel (PTX), docetaxel (DTX) and cis-platin 
could be esterified with acid anhydride or carboxylic acid to obtain active keto sites for 
hydrazone formation.
Cheng et al, observed the pH-dependent release of DOX by formulating folic acid 
conjugated poly(ethylene glycol) (PEG)5000-PAMAM(G4) dendrimers using hydrazine linkers. 
In vitro release of DOX from PAMAM-DOX conjugate was evaluated at pH 4.5, 5.5 and 7.4, 
which was found to be 42, 28 and 8%, respectively. The results revealed the stability of 
hydrazine linker at pH 7.4 and lability at acidic pH [53]. In another report an amphiphilic linear-
dendritic prodrug (mPEG-PAMAM-DOX) for the co-delivery of 10-hydroxy-camptothecin 
(HCPT) and DOX using acid-labile hydrazine linker was design and revealed acid responsive 
release behavior. It was observed that as the pH is decrease by 7.4 to 4.5 the release is increased 
from 5 to 60% revealing pH dependent cleavage of hydrazone linkage [54]. Likewise, She et al, 
designed mPEGylated peptide dendron-DOX (dendron-DOX) conjugate and demonstrated pH-
dependent release of DOX using hydrazone linkage. The in vitro release revealed 20 and 80% 
drug release at pH 7.4 and 5, respectively [55]. Same research group also observed the release of 
DOX from galactose functionalized PEGylated dendrimer-DOX conjugates having hydrazone 
linkage. Due to cleavage of pH sensitive hydrazone linker, the release of DOX from the 
conjugates at pH 5 was much rapid than those at pH 7.4 [56]. 
Hydrazone linkage was successfully employed for conjugation of DOX to pH-sensitive 
drug-dendrimer conjugate-hybridized gold nanorods (PEG-DOX-PAMAM-AuNR). Drug release 
studies revealed that the release of DOX from the conjugate was negligible at pH 7.4, but was 
boosted considerably at weak acidic pH [57].
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A biodegradable hyper-branched HPMA copolymer-DOX conjugate was synthesized 
with cathepsin B sensitive peptide GFLGK and the anticancer drug DOX was attached to the 
branched copolymer via a pH-responsive hydrazone bond. As compared to traditional 
copolymers, the biodegradable multiblock HPMA copolymer-drug conjugates resulted in 
enhanced anticancer efficacy with no obvious side effects [58]. 
4.1.2 Acetal linker
Chemically an acetal is an organic molecule having a central carbon atom attached to two 
oxygen atoms by single bond. For ketone derivatives, they are called ketals and are commonly 
used as protecting groups in organic synthesis and for the design of acid-sensitive linkages [59]. 
Acetal linkages can be formed by reaction between an aldehyde or ketone and alcohol [60] or 
between alcohol or phenols and vinyl ether, in the presence of acid catalysts [61]. Acetals are not 
stable to acidic environment and are very readily hydrolyzed back to the carbonyl and alcohol. 
However, there are only a few reports of application of acetals as pH-sensitive linkers for 
anticancer drug delivery using dendritic system. 
The pH-responsive micelles based on PEO-dendritic polyester copolymer anchoring an 
anticancer drug, DOX by acid-labile acetal groups demonstrated the hydrolysis of acetal groups 
at acidic pH. The DOX was selectively released in tumor vicinity including endosomes and 
lysosomes [62].
4.1.3 Cis-acotinyl linker
The cis-aconityl, a derivate of natural aconitic acid is commonly used for controlling the 
release of amine group containing drugs. The interaction between cis-aconitic anhydride and an 
amine drug leads to a ring opening, which has a carboxylic functionality for conjugating to 
dendrimer. In mildly acidic conditions, the amide bond undergoes hydrolysis to release the drug. 
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In an interesting study Yabbarov et al, formulated a conjugate comprising rAFP3D 
(alpha-fetoprotein) acting as targeting ligand, PAMAM G2 dendrimer and DOX. The cis-
aconityl linkage was used to conjugate DOX with PAMAM G2 dendrimer. The in vitro release 
study demonstrated that the release of DOX was found to be pH dependent with 8, 75 and 90% 
drug release at pH 7.4, 6.0 and 5.5, respectively [63]. Zhong and Da Rocha synthesized 
PEGylated G3 PAMAM-DOX conjugate by using an acid labile (cis-aconityl) and acid non-
labile (succinic) linker. In vitro release studies conducted at pH 7.4 and 4.5 revealed 9 and 85% 
DOX release, respectively [64]. 
Similarly, Zhu et al, synthesized PEGylated PAMAM G4 dendrimers with different 
degrees of PEGylation and conjugated with variable amounts of DOX through cis-aconityl and 
succinic linker and term as PPCD and PPSD prodrugs, respectively. The in vitro release study 
showed negligible amounts of drug released from PPSD prodrug at varied pH values and pH 
dependent drug release from PPCD prodrug. The cytotoxicity study on murine B16 melanoma 
cells reveals significant toxicity by PPCD prodrug and negligible toxicity by PPSD prodrug [65].
4.1.4 Boronate ester linkers
Reaction between boronic acid and 1,2-diol or 1,3-diol in aqueous medium leads to the 
formation of boronate ester, a covalent ester bond. The bond is stable at pH higher than its pKa 
value but unstable at pH lower than its pKa value. Therefore, boronate ester can be used as pH 
sensitive linker to construct pH responsive assemblies [66, 67]. 
Boronate ester bond can be used to prepare bortezomib prodrugs. Catechol-modified 
PAMAM dendrimer was conjugated to an anticancer drug, Bortezomib via the boronate ester 
bond. The results revealed the drug release in acidic environment (pH 6.5) and no release at 
physiological pH [68].
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4.1.5 N, O-chelate linker
A pH-responsive mPEGylated peptide dendrimer-linked diaminocyclohexyl platinum (II) 
(dendrimer-DACHPt) conjugate was prepared by Pan et. al. The DACHPt has a molecular 
structure, is and activity closely related to oxaliplatin. To achieve pH-sensitive DACHPt 
conjugation, the N,O-chelate was utilized to link the DACHPt to the dendrimers. The conjugate 
was pH-responsive and released drug significantly faster in acidic environments (pH 5.0) than 
pH 7.4. The result revealed that the conjugates suppressed tumor growth better than clinical 
oxaliplatin without inducing toxicity in an SKOV-3 human ovarian cancer xenograft [69].
5. Redox-responsive dendrimers
Control over release of drug in response to difference in the reduction potential between 
tumors and normal tissue is frequently employed strategy in cancer therapy. There is highly 
regulated redox status inside the normal cell balancing the reduced and oxidized species. This 
balance gets disturbed in cancerous cells, which leads to accumulation of ROS and results in 
oxidative stress. To overcome oxidative stress, cells recruit ROS scavengers such as glutathione 
(GSH) and vitamins C and E. The significant difference (about 4-fold) in GSH concentration 
intracellularly (2-10×10-3 M) and extracellularly (2-20 µM) in cancerous tissue have made GSH 
responsive assemblies most explored for reductive responsive drug delivery systems [70-72]. 
Further, a specific reducing enzyme, gamma-interferon-inducible lysosomal thiol reductase 
(GILT) modulates the redox potential of endosomal compartment in the co-presence of a 
reducing agent such as cysteine [73-75].
The frequently used redox-reponsive linker for dendrimer drug conjugate is disulphide 
linker. The elevated GSH mediates disulfide bond cleavage reactions via reduction or dithiol-
disulfide exchange process (Figure 2). Besides disulfide bonds, diselenide or ditellurium bonds 
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are also used as redox responsive linkers. The diselenide bond is more sensitive than disulphide 
bond towards stimuli as the cleavage energy of diselenide bonds is lesser as compared to 
disulfide bonds [76-78].
A novel stimulus responsive conjugate of dendrimer and gold nanoparticle (GNP) was 
developed for the delivery thiolated anticancer drugs by Wang et al. Dendrimer-encapsulated 
gold nanoparticles (DEGNPs) were synthesized and thiolated anticancer drugs are attached 
through the Au-S linkage. The conjugate exhibited an “Off-On” release behavior in the presence 
of thiol-reducing agents such as glutathione and dithiothreitol. The developed conjugate showed 
much reduced cytotoxicity as compared to the free anticancer compounds [79]. 
A new class of disulfide cross-linked G2 PAMAM dendrimers was prepared as non-viral 
gene carrier to enhance transfection efficacy and to reduce cytotoxicity. Disulfide containing 
linker 3,3′-dithiodipropionicacid-di(N-succinimidyl ester), (DSP) was used to cross-link G2 
PAMAM dendrimers to form supra-molecular structures (G2DSPs). The cross-linked conjugate 
was degraded due to disulfide bond reduction after gene transfection and this regulated the 
release of DNA in a controlled manner [80].
In a recent study a redox responsive peptide conjugated tumor targeted nano vehicle 
(PSPGP) composed of branched PEG with G2 dendrimers was synthesized for co-delivery of 
PTX and siTR3 for treatment of pancreatic cancer. The assembly was conjugated with PTP 
(plectin-1 targeted peptide, NH2-KTLLPTP-COOH), a biomarker for pancreatic cancer. Redox-
responsive disulfide bonds were used to link the PTX and siTR3 to the conjugate. The complex 
showed inhibition in tumor growth and promoted cancer cell apoptosis [81]. 
Lim et al, synthesized 3 conjugates of PTX with PEGylated triazine dendrimer. The 
dendrimer construct 1 includes an ester linker, whereas dendrimer construct 2 and 3 include a 
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disulfide linker. Cytotoxicity studies using an MTT-based assay and PC-3 cells revealed IC50 
values of 4.5 and 29 nM for free PTX and construct 1, respectively and increased in construct 2 
and 3 from 74 to 26 nM and 13nM in the presence of 1 mM glutathione and 1 mM dithiothreitol, 
respectively [82]. 
Reduction-responsive amphiphilic dendritic copolymer (TPP-S-S-G3) with disulfide-
linkages between dendrimer (PEG-G3-OH) and porphyrin (TPP, photosensitizers) for the 
combined chemotherapy and photodynamic therapy (PDT) was developed. The copolymer self-
assembled into micelles in aqueous solution. The results showed fast uptake and release of DOX-
loaded TPP-S-S-G3 micelles by MCF-7 cells [83]. Nguyen et al, studied Heparin (Hep) 
conjugated to PAMAM G3.5 (P) via redox-sensitive disulfide bond (P-SS-Hep). The dendrimer 
complexes were found to promote redox-sensitive drug release intracellularly. In the cancer cells 
the disulfide linkage cleaved and enabled the release of drug. Hence, providing evidence of 
potential of redox sensitive nanocarriers in cancer chemotherapy [84]. 
Dual responsive PAMAM dendrimers that responded to variation in reduction potential 
and pH have been used for the delivery of DOX. The redox-responsive functionality is imparted 
using disulfide linkage between PAMAM dendrimers and PEG with DOX loaded into the 
hydrophobic core of the conjugates. The release study demonstrated redox and acid trigger 
release behavior of DOX [85]. For tumor-targeted drug delivery an asymmetric bow-tie 
PAMAM dendrimer (ABTD) scaffold has been developed using disulfide unit as self-immolative 
linker. The results revealed a remarkable selectivity of ABTD scaffold to cancer cells as 
compared to human normal cells and demonstrated reduction responsive release behavior [86]. 
A GSH-triggered self-immolative dendritic prodrug has been designed for cancer 
therapy. The assembly comprised an anticancer drug Camptothecin (CPT), a reduction cleavable 
18
linker (2,4-dinitrobenzenesulfonyl, DNS) and a near infrared (NIR) fluorescent dye 
(dicyanomethylene-4H-pyran, DCM). Cleavage of the DNS linker in the presence of GSH 
released the drug and activated NIR fluorophore, which could aid to track the released drug [87].
To develop highly efficient and safe gadolinium (Gd)-based MRI contrast agents with 
minimum bio-accumulation and least detrimental effect on the body, Guo et.al, develop 
biodegradable Gd-based polymeric contrast agents with a biocleavable disulfide linker. 
Biodegradable poly[N-(1,3-dihydroxyprpyl) methacrylamide] copolymers (pDHPMA) were 
synthesized and small molecular Gd-chelate (Gd-DOTA) was conjugated onto the copolymer 
backbone through a sulfide bond or a GSH-sensitive cleavable disulfide bond to produce two 
novel Gd-mCAs (pDHPMA-Cy5.5-DOTA-Gd or pDHPMA-Cy5.5-SS-DOTA-Gd) for tumor 
diagnosis. The developed contrast agents demonstrated enhanced relaxation efficiency, improved 
pharmacokinetics and better passive targeting through EPR effect as compared to Gd-
diethylenetriamine pentaacetic acid (DTPA-Gd) [88].
6. Enzyme-responsive dendrimers
Changes in the level and activity of various enzymes are observed in cancer etiology. As, 
cellular metabolic processes are augmented in cancer tissue, the enzymes that regulate these 
processes are commonly overexpressed. This dysregulation of their expression is considered as 
characteristic feature of the cancer and is utilized as a tool in diagnostics. Along with 
diagnostics, such dysregulation is utilized in managing the disease condition by programming the 
drug delivery system for active targeting and to control the release of drugs. The on-demand drug 
release, governed by enzyme is designed by integrating specific linkers that can be recognized 
and degraded by the enzymes overexpressed in the extracellular or intracellular environment of 
the tumor [89, 90]. A variety of enzymes are found to be upregulated in tumor tissues including 
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cathepsins, matrix metalloproteases (MMPs), hyaluronidase, azoreductase, phospholipase and 
many more [91].
Further, the advent of enzyme responsive self-immolative dendrimers as molecular 
amplifiers has translated the release of drug on enzymatic stimulation. Incorporation of drug 
molecules as the tail units and an enzyme substrate as the trigger in self-immolative dendrimers, 
generated a prodrug unit that was triggered upon a single enzymatic cleavage. The enzymatic 
trigger commonly utilized for the same is 38C2 antibody, penicillin-G-amidase and β-
galactosidase [92, 93].
Cathepsins, a group of proteolytic enzymes predominantly located in endo/lysosomal 
vesicles, are involved in the degradation of extracellular matrixes (ECM) of the tumor tissue and 
thus contributing to infiltration of the tumor cell. Out of various cathepsins, cathepsin B is one of 
most explored lysosomal proteases due to its high expression in various types of cancers 
including prostate, breast, lung, brain, endometrium and colorectum. Invasive and metastatic 
cancers are the results of abnormal regulation of cathepsins [94, 95]. 
Lee et al, synthesized dendrimer-methoxy PEG (MPEG)-DOX conjugates using a 
cathepsin B-cleavable peptide, glycyl phenylalanyl leucyl glycine tetra-peptide (Gly-Phe-Leu-
Gly) for anticancer drug targeting (Figure 3). The results revealed improved anticancer activity 
in an in vivo CT26 tumor xenograft model i.e. the volume of the CT26 tumor xenograft was 
significantly inhibited [96]. 
Cathepsin B-cleavable peptide (Gly-Phe-Leu-Gly) was successfully used to develop a 
novel enzyme-responsive PEGylated lysine peptide dendrimer-gemcitabine (GEM) conjugate 
(Dendrimer-GEM) based nanoparticle. The results indicated suppressed relative tumor volumes 
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(86.17±38.27%) and a 2-fold higher value of tumor growth inhibition (∼90%) than GEM, 
establishing enhanced antitumor efficacy without obvious systemic toxicity [97].
In another study cathepsin B-cleavable peptide was utilized by Zhang and coworkers to 
develop mPEGylated peptide dendrimer-DOX (dendrimer-DOX) conjugate-based nanoparticles, 
which demonstrated significantly high antitumor activity and substantially reduced DOX-related 
toxicities [98]. Similar peptide along with a pH-sensitive hydrazone bond was exploited by Chen 
et al, for the preparation of a novel pH/enzyme sensitive dendritic polymer-DOX conjugate for 
cancer treatment. The result revealed high accumulation of DOX into tumors due to prolonged 
blood circulation time. In vivo studies revealed better antitumor efficacy of the conjugate in 
comparison with free DOX [99].
Wang et al, designed an enzyme-stimuli nanogel based on G4 PAMAM dendrimers using 
elastase cleavable bond (Ac-arg-ala-ala-asp-D-tyr-cys-NH2) (RAADyC). Neutrophil elastase 
(NE) is detected in different types of cancers, and its concentration is associated with the cancer 
stage, grade, and the survival [100].
Azoreductase, an enzyme over-expressed in hepatocellular carcinoma cells, can work as a 
trigger to induce drug release. Medina et al, synthesized a series of aromatic azo-linkers (L1-L4), 
which were used to conjugate DOX to G5 PAMAM dendrimers. To study the effect of 
electronegativity on susceptibility to cleavage by azoreductase enzymes, these linkers are 
incorporated with electron-donating oxygen (O) or nitrogen (N) groups. Results revealed the 
release of 4-8, 17, 60, and 100% of the conjugated DOX molecule from dendrimers having 
linkers L1 to L4, respectively. Increase in electronegativity increases susceptibility to cleavage 
by azoreductase enzymes [101].
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Phospholipase C (PLC) enzyme, an important regulator of membrane phospholipid 
metabolism is found to be overexpressed in many cancers and participates in cancer cell 
progression and differentiation [102,103]. Zhang et al, synthesized enzyme-responsive 
phosphoramidate (PAD) dendrimers for delivery of DOX. The dendrimers were degradable in 
the presence of PLC but found to be stable in phosphate buffer saline (PBS). The phosphite ester 
bonds in PAD dendrimers is degraded by PLC. The results revealed improved therapeutic 
efficacy of the conjugate with reduced toxicity in athymic nude mice bearing xenografts of 
MCF-7/ADR breast cancer [104].
A dendritic prodrug with an anticancer agent camptothecin (CPT) and a trigger that 
allowed activation by penicillin-G-amidase was designed and synthesized. Cell-growth inhibition 
assays demonstrated that the toxicity of the dendritic prodrug was found to be dependent upon 
incubation with penicillin-G-amidase [105]. Shamis et al, prepared a self-immolative assembly 
for synergistic combinational therapy in cancer utilizing DOX and CPT as tail units and a 
catalytic antibody 38C2 cleavable retro-aldol retro-Michael focal trigger [106]. 
In an effort to improve therapeutic index of an anti-cancer drug, gemcitabine (GEM), a 
stimuli-responsive dendritic polyHPMA copolymer was designed and synthesized GEM 
(Dendritic polyHPMA-GEM) prodrug via one-pot synthesis of RAFT polymerization by Dai and 
coworkers. GEM was conjugated onto the dendritic polymeric carrier via an enzyme-responsive 
linker glycyl-phenylalanylleucyl-glycine tetra-peptide (GFLG), which was found to be stable in 
blood circulation system and degraded in the presence of Cathepsin B only. The results revealed 
that the designed stimulus-responsive dendritic copolymer-GEM prodrug may a safe, effective 
and enzyme-responsive anticancer agent [107].
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 Polymer-drug conjugates has significantly improved the anti-tumor efficacy of 
chemotherapeutic drugs and alleviated their side effects. In this regard a biodegradable diblock 
N-(1,3-dihydroxypropan-2-yl) methacrylamide (DHPMA) copolymer-DOX conjugate (a self-
aggregation-induced nanoprodrug) via one-pot of RAFT polymerization and conjugate chemistry 
was developed. Notably, the nanoprodrug had a significantly prolonged blood circulation time 
with an elimination half time of 9.8 h. It displayed high accumulation within tumors, and 
improved e in vivo therapeutic efficacy against 4T1 xenograft tumors compared to free DOX. 
The authors demonstrated that the diblock pDHPMA-DOX nanoprodrug with a controlled 
molecular structure exhibited an enhanced antitumor efficacy against 4T1 breast tumors through 
the inhibition of cell proliferation and antiangiogenic effects and alleviated side effects, showing 
a great potential as an efficient and safe anticancer agent [108].
7. Temperature-responsive dendrimers
Among external stimuli, temperature trigger drug release has shown significant potential. 
However, the use of temperature as a trigger requires external heating methodology that can heat 
the tumor area locally and thus respond to temperature variation [109]. Modification of 
dendrimer surfaces with oligo- and poly-ethylene oxide-based functionality endow them with 
temperature-sensitive characteristics [110]. 
There is an inverse relationship between aqueous solubility and temperature for 
temperature sensitivity functionalities. As temperature is increased the degree of hydrogen 
bonding between the temperature sensitive moieties and water decreases, and this will leads to 
phase separation. Lower critical solution temperature (LCST) or the cloud point is the phrase 
used demark such phase transition and is specific for a moiety [111]. Most commonly used 
thermo-responsive material includes PEG and poly(N-isopropylacrylamide) (pNIPAM). These 
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functional groups become hydrated due to hydrogen bonding with water and the application of 
temperature trigger breakdown of these weak interactions causing them to lose its hydrophilicity 
[112,113].
Thermosensitive pNIPAM polymer-conjugated PAMAM dendrimer has efficiently 
delivered Malloapelta B (Mall B) against HepG2 cancer cell proliferation. The conjugate showed 
high encapsulation of Mall B and demonstrated slow controlled release, which significantly 
inhibited HepG2 cancer cell proliferation [114]. Wu et al, synthesized G4 thermosensitive 
dendrimers based on oligo (ethylene glycol) (OEG) conjugated with an antitumor agent, GEM. 
The prepared dendrimers were compared with that of GEM-conjugated PAMAM dendrimers. 
The GEM-OEG based dendrimers exhibited thermal responsive release behavior and better 
tumor accumulation and penetration than the GEM-conjugated PAMAM [115]. 
A temperature responsive dendrimer conjugate was prepared for gene silencing through 
intracellular small interfering RNA (siRNA) release. The pNIPAM and phenylboronic acid were 
conjugated with PAMAM dendrimer for the design temperature responsive system. The 
phenylboronic acid improves the stability and cellular uptake while pNIPAM is responsible for 
temperature responsive behaviors at lower critical solution temperature. The results revealed that 
gene silencing efficacy was significantly increased by cool treatment after its cellular uptake 
with minimal toxicity [116].
Though, temperature-sensitive materials for dendrimer drug conjugate is numerous, a few 
are potentially utilized for temperature-responsive drug release. This is probably due to difficulty 
in controlling the release of the drug during phase transition and the safety concerns of the 
temperature-sensitive polymers above LCST for in vivo applications. Further, it is very difficult 
to heat localized tissues without hurting normal tissues. 
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8. Light-responsive dendrimers
As external stimuli, light is most explored due to some obvious advantages such as non- 
invasiveness and prospect of temporal and spatial accuracy. The principle governing the release 
of drug from dendrimers using light as a stimulus is based on- (i) the absorption of light by 
photosensitive ligands that would trigger reversible physical changes (e.g., trans-cis 
isomerization) and cause release of the encapsulated drugs and (ii) the absorption of light by 
photosensitive ligands causes irreversible cleavage reaction. The most common photosensitive 
ligands for the former are azobenzene derivatives and for later are o-nitrobenzyl ether (or ester) 
derivatives grafted on the surface of dendrimers [117].
The commonly used light triggers includes ultraviolet (UV) (200-400 nm), visible (400-
700 nm) or near-infrared (NIR) (700-1000 nm) light. However, UV and visible light usage gives 
poor tissue penetration as well as leads to phototoxicity. NIR light irradiation has deeper tissue 
penetration with the penetration depth of up to 2 cm with less phototoxicity and thus preferred. 
Nevertheless, NIR light has inherent low energy and due to this two-photon excitation technique 
would be considered ideal for photobiological applications using NIR light irradiation or the 
application of upconversion nanoparticles, which can convert adsorbed NIR light to UV 
irradiation (Figure 4) [118-120].
Choi et al, designed folic acid conjugated G5 PAMAM dendrimer and photocaged DOX 
using the photocleavable group ortho-nitrobenzyl (ONB) (Figure 5). The in vitro cytotoxicity 
studies using KB cell-based assay revealed release of DOX and cytotoxicity on exposure to UV 
light [121]. Similarly, in another study same group of researchers designed targeted PAMAM 
dendrimer for the delivery of methotrexate (MTX). The in vitro cytotoxicity study using KB cell-
based assay demonstrated MTX release through a light-controlled mechanism following 
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exposure to UV light [122]. Sun et al, designed DOX loaded Janus-type dendritic structure by 
linking a hydrophobic dendron (diazonaphthoquinone (DNQ)-decorated G3 PAMAM) and a 
hydrophilic dendron (lactose (Lac)-decorated Gm PAMAM dendrons). The DNQ, undergoes a 
Wolff rearrangement to form a ketene, on exposure to light. These Janus dendritic structure gets 
self-assembled into micelle in aqueous solution and gets disassemble on exposure to NIR light. 
The results presented a photo-triggered cytotoxicity and revealed doubling of DOX release on 
irradiation to NIR [123].
Coumarin, a natural dye, with high two-photon cross sections is utilized as photocages 
for the light responsive release of chemotherapeutic drugs [124]. Wang et al, synthesized a light 
responsive construct for the co-delivery of 5-Flurouracil (5-Fu) TRAIL plasmid for cancer 
therapy. The anticancer moieties were loaded on amphiphilic G1 dendrimer-coumarin conjugate 
(G1-CM). Coumarin acts as photoresponsive group and on exposure to light leads to degradation 
of the assembled structure and exhibits a light-responsive drug release profile [125].
Thioacetal ortho-nitrobenzaldehyde TNB(OH) photolinker was utilized for the 
construction of TNB-caged DOX conjugates. The constructed caged conjugates are then 
integrated with 2 folic acid functionalized nano-assemblies. First is, G5 PAMAM dendrimer and 
second is upconversion nanocrystal (UCN) conjugate with protoporphyrin IX (PPIX) as 
cytotoxic photosensitizer. Cellular toxicity studies in KB carcinoma cells revealed that each 
nano-assembly exhibit cytotoxicity on exposure to UV or NIR (980 nm) [126]. However, despite 
various obvious benefits of light as a stimulus for drug release, its application is limited in the 
treatment of solid tumor due to the ambiguity regarding penetration depth, irradiation time and 
effective area.
9. Smart dendrimers in gene delivery
26
An alternative strategy to traditional radiotherapy and chemotherapy, gene therapy is now 
recognized as a potential therapeutic modality for cancer treatment. Gene therapy has been 
extensively explored for the management of cancer, as approximately 65% of the clinical trials in 
gene therapy have been designed at the treatment of various types of cancers [127]. To realize 
gene transfer complex cellular and tissue barriers must be overcome without disrupting vital 
regulatory mechanisms to deliver the tailored therapeutic gene for augmentation or suppression 
or repair, using a vehicle called vector [128]. 
In addition to carrier of chemotherapeutic agent and contrast agent in molecular imaging 
for cancer treatment and prognosis, dendrimers are also considered as non-viral vector for gene 
therapy. In contrast to viral vectors, dendrimers as a non-viral vector offer distinct advantage 
including target-cell specificity and resistance to repeated administration. Further, the 
biodegradable dendrimers are preferred for gene delivery as compared to the non-degradable 
dendritic vectors, due to their reduced toxicity and degradability. The PAMAM dendrimers, 
dendritic polyglycerols and peptide dendritic polymers are the commonly investigated vectors 
for gene therapy [129, 130]. 
Alternatives to viral-mediated gene delivery, dendrimers are now being largely 
investigated as an effective non-viral mediated gene delivery system. Though, viral vectors have 
high transfection efficacy but are accompanied by high immunogenicity, cytotoxicity and 
production problems. Owing to possibility of multifunctionality, dendrimers are perceived as 
non-viral vector that can overcome these limitations [131]. However, cationic dendrimers is 
associated with serious toxicity and thus a key challenge in clinical gene therapy is to prepare 
dendritic vector with high transfection efficacy and low toxicity. Fluorinated dendrimer, a new 
class of non-viral gene carriers exhibits interesting physicochemical properties, with efficient 
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cellular internalization and less toxicity [132,133]. A structure-activity relationships (SAR) study 
for DNA and siRNA delivery based on different dendrimer generations and fluorination degrees 
reveals that fluorination significantly improves the transfection efficacy of G4-G7 PAMAM 
dendrimers. Fluorination on G5 dendrimer yields the most efficient polymers in gene delivery, 
and the transfection efficacy of fluorinated dendrimers depends on fluorination degree. All the 
fluorinated dendrimers cause minimal toxicity on the transfected cells at their optimal 
transfection conditions [134].
A series of fluorodendrimers was synthesized, by reacting PAMAM dendrimers with 
heptafluorobutyric anhydride, as non-viral gene vectors. The synthesized conjugate self-
assembled to form uniform polyplexes with promising properties at a low nitrogen-to-
phosphorus ratio and have low charge densities and relatively weak DNA associations. Uniform 
polyplexes ensures reproducible gene transfection. A low charge density indicates low 
cytotoxicity and weak DNA association, which is beneficial for efficient DNA unpacking in the 
cytoplasm [135].
The interaction of G5 PAMAM dendrimers with perfluoro acid anhydrides resulted in the 
development of fluorinated dendrimers with high transfection efficacy and low toxicity. The 
study revealed that fluorination of the dendrimers improved the transfer across cell as well as the 
endosome/lysosome membrane facilitating endosomal escape. Further, this class of dendrimer 
has shown to form polyplexes with genes at low nitrogen to phosphorus (N/P) ratios to minimize 
the toxicity on the transfected cells [136].
A stimulus-responsive fluorinated bola-amphiphilic dendrimer bearing ROS-sensitive 
thioacetal in the hydrophobic core and positively charged PAMAM dendrimer at the terminals 
was synthesized for the delivery of siRNA in cancer cells. The conjugate combine the 
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advantageous delivery features of both lipid and dendrimer as a non-viral vector. The result 
revealed that the conjugate capable of interacting and compacting the negatively charged siRNA 
into nanoparticles to protect the siRNA and promote cellular uptake [137].
A heptafluorobutyric acid modified G4PAMAM dendrimer (G4-F735) has been used as a 
nonviral vector to deliver plasmid encoding TNF-related apoptosis-inducing ligand (pTRAIL) 
gene for cancer treatment to achieve both excellent transfection efficacy and low toxicity. The 
results revealed much higher TRAIL gene transfection efficacy than a series of transfection 
reagents including poly(ethylene imine) (PEI), SuperFect and Lipofectamine 2000 and exhibited 
minimal toxicity in vitro [138].
For the investigation of fluorous effect on transfection efficacy and cytotoxicity, Wang 
and Cheng synthesized a series of fluorobenzoic acid (FBA)-modified dendrimers as non-viral 
gene vectors. The results demonstrated that the transfection efficacy increases with increasing 
number of fluorine atoms on the aromatic rings. The modified dendrimers were found to be 
superior as compared to the polymer-based and lipid-based commercial reagents such as 
SuperFect, PolyFect, and Lipofectamine 2000, respectively. Fluorination on the aromatic rings 
significantly improves the transfection efficacy of benzoic acid-modified dendrimers [139]. 
In a study fluorodendrimer was prepared by reacting G2 PAMAM dendrimer with 
heptafluorobutyric anhydride for the co-delivery of fluorinated anticancer drugs (sorafenib or 5-
Fu) and therapeutic genes (TRAIL plasmid) in synergistic cancer therapy. The results revealed 
high drug loading and gene transfection efficacy with minimal toxicity [140]. 
10. Conclusion
The synergy that exists between experimental and theoretical studies opens new avenues for the 
use of dendrimers as versatile drug delivery systems. The possibility of diverse functionalization 
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on dendritic structure paves the path for delivery of drugs in spatial-, temporal- and dosage-
controlled fashions for cancer therapy. The use of stimuli responsive smart linkers facilitates the 
delivery of payloads in a controlled manner on specific triggers. The incorporation of pH and 
redox responsive systems into dendrimers, has attracted significant interest. Various functional 
groups have been utilized in dendritic assemblies such that a pH sensitive linker would provide 
stability to the assembled nanostructure stable at neutral pH 7.4, but would respond to a lower 
pH. The use of pH-, redox-, enzyme-, thermal- and light-responsive ligands potentiate the target 
functionalized dendrimers in delivering anticancer bioactives in an efficient and safer manner.
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Table legend:
Table 1. Acid-responsive chemical bonds and corresponding degradation products under acidic 
environment [Modified and reproduced with permission from Ref 42]
Figure legends:
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Fig 1. Dendrimer-doxorubicin conjugate via hydrazone linkage [Modified and reproduced, with 
permission from Ref 32]
Fig 2. Cleavage of disulfide bond between dendrimer–drug conjugates via GSH [Modified and 
reproduced, with permission from Ref 32]
Fig 3. Cleavage of glycyl phenylalanyl leucyl glycine tetra-peptide (GFLG) between dendrimer-
doxorubicin conjugates by Cathepsin-B [Modified and reproduced, with permission from Ref 32]
Fig 4. Photo-cleavable groups: (a) Ortho-nitrobenzyl (ONB) group and (b) Coumarin [Modified 
and adopted from Ref 118].
Fig 5. Cleavage of ortho-nitrobenzyl (ONB) linker in dendrimer-doxorubicin conjugate upon UV 
light irradiation [Modified and reproduced, with permission from Ref 32]
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Table 1. Acid-responsive chemical bonds and corresponding degradation products under acidic environment [Modified and reproduced with 
permission from Ref 42]
Acid-responsive 
chemical bond
Structure Degradation products Reference
Cis-Aconityl
Hydrazone
Acetal
[42]
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Fig 1. Dendrimer-doxorubicin conjugate via hydrazone linkage [Modified and reproduced, 
with permission from Ref 32]
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Fig 2. Cleavage of disulfide bond between dendrimer–drug conjugates via GSH [Modified 
and reproduced, with permission from Ref 32]
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Fig 3. Cleavage of glycyl phenylalanyl leucyl glycine tetra-peptide (GFLG) between 
dendrimer-doxorubicin conjugates by Cathepsin-B [Modified and reproduced, with 
permission from Ref 32]
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Fig 4. Photo-cleavable groups: (a) Ortho-nitrobenzyl (ONB) group and (b) Coumarin 
[Modified and adopted from Ref 118].
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Fig 5. Cleavage of ortho-nitrobenzyl (ONB) linker in dendrimer-doxorubicin conjugate upon 
UV light irradiation [Modified and reproduced, with permission from Ref 32]
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2Abstract
Optimization of biological performance of a carrier in cancer drug delivery depends on the 
targeting potential of the delivery system and its ability to control the drug release precisely. 
Dendrimers has emerged as a potential carrier of anticancer drugs due to some unique properties 
such as mono-dispersity, defined structure, amenability for functionalization using diverse 
ligands and its low-nanometer size. The dendrimers could be decorated to make them smart 
enough to carry the drug to the desired locus and release it in a controlled manner. The 
introduction of stimuli responsive functionality on dendrimers allows the release of payloads in 
response to a specific trigger only. These triggers could be endogenous in nature (acid, enzyme, 
and redox potentials) or it could be applied externally (light and temperature). These smart 
functionalities synergize the targeting of dendrimers and enable dendrimer-based anticancer drug 
delivery more efficient and safer. This review highlights the potential of stimuli responsive 
strategy for the controlled release of anticancer drug from dendritic assemblies. 
 Keywords: Dendrimers; Drug release; Cancer; Drug targeting; Toxicity; Anticancer drug  
31. Introduction
Optimizing the outcome of already existing drugs is currently the focusing area of 
research in view of improving physicochemical, biodistribution and pharmacokinetic properties 
of the drugs to enhance therapeutic benefit with minimal side-effects. The size manipulation at 
the molecular level could leads to new intrinsic properties and would be translated as 
technological innovations for improving the outcome of conventional systems. In field of 
medicine such technological innovations are termed as nanomedicine. The aim of nanomedicine 
is to diagnose a disease in its initial stage and to treat it rapidly and specifically, therefore, 
restrict long-term damage [1]. The field of nanomedicine could be prudently utilized in the 
management of the world’s most deadly disease cancer which is responsible for about 22% of all 
human deaths annually from non-communicable diseases [2,3]. 
With hundreds of signaling pathways and multiple causes that respond differently to 
various treatments, cancer remains an ongoing challenge with enormous health and financial 
burdens on patients and society. The stage of the cancer is the decisive factor in opting the 
treatment regimen via surgery, radiation, chemotherapy, biological and hormone therapy. 
Nonetheless, chemotherapy remains the mainstay option for cancer management and depending 
on type of cancer and its advancement, it is used as adjuvant with surgery, radiation therapy, or 
biological therapy [4].
Non-selective biodistribution, low aqueous solubility with poor membrane permeability 
and rapid clearance, hypersensitivity reactions, and advent of multidrug resistance (MDR) are the 
major challenges in conventional chemotherapy [5]. Thus, a drug therapy that shows 
reproducibility in pharmacokinetic behavior and is target specific is sought. A stable, 
monodisperse, well-defined system could ensure the reproducibility in pharmacokinetic behavior 
4of a therapy in-vivo. This realization leads to the synthesis of hyperbranched polymers termed as 
dendrimers [6]. 
2. Dendrimers: An outline
Dendrimers, a class of artificial macromolecules, are nanosize, monodisperse, multivalent 
polymeric systems with well-defined structure. These unique exciting features ensure a pivotal 
role of dendrimers in the management of cancer. Structurally, a dendrimer has a treelike 
molecular construction and comprises of three main architectural components including a core, 
branching layers (termed as generations) consist of repeating units surrounding the internal core 
and a multivalent external surface. Generation number (G) signifies the number of focal points 
from the core towards the surface and is used to determine molecular weight and the number of 
terminal functional groups [7]. Drugs could either be encapsulated within dendrimers internal 
cavity or bound to their surfaces through hydrophobic, electrostatic or covalent interactions. The 
immense potential in this class of molecular construct leads to synthesis of various classes of 
dendrimers, such as poly(propylene imine) (PPI), poly(amidoamine) (PAMAM), chiral, 
amphiphilic, micellar, Tecto, Frechet and Janus dendrimers and are also commercially available 
[8].
Due to highly dense structure, perfect chemical definition and a well-defined number of 
surface functionalities, dendrimers could be adaptable to multifunctional modifications with 
valuable flexibility for grafting different chemical moieties on the surface, at the core, or within 
the structure. The most promising feature of dendrimers is their multi-valency, which presents 
multiple arrays of ligands to the target bearing multiple receptors. This leads to a greatly 
increased interface between the dendrimer and the target enhancing affinity and activity [9,10].
2.1 Comparative account of linear polymer, dendritic polymers and dendrimer
5Dendritic polymers considered as branched polymeric architectures, are classified into 
random hyperbranched polymers, dendrigraft polymers, dendrons, and dendrimers based on 
degree of structural control [11]. In general, branched polymers have sophisticated topological 
structures and exciting physico-chemical and biological properties. In comparison to their linear 
analogues, branched polymers have three-dimensional globular structure, lower solution/ melting 
viscosity, smaller hydrodynamic radius, higher degree of functionality, increased encapsulation 
capabilities, enhanced solubility and minimal molecular entanglement. Owing to high 
functionality, dendritic structures, allows dense incorporation of drugs, imaging and targeting 
agents [12]. Monodisperse nature of dendrimers, in addition, provides reproducible 
pharmacokinetic behavior as compared to linear polymers, which are generally polydisperse and 
thus containing varying molecular weighed fractions among a given sample. Also, controlled 
globular shape of dendrimers other than entangled and coiled structures of linear polymers 
enhances their biological properties [13]. Furthermore, prospect of surface engineering due their 
high density of functionalities allow to tune their thermal, mechanical, rheological, solution 
properties (size, conformation, solubility), and biocompatibility. These features can further 
improve the biodistribution and pharmacokinetic profile, tendency of crossing biological 
barriers, blood circulation time and tumor penetration [14-16].
2.2 Toxicologial profile of dendrimers and remedies
The emergence of dendrimers is foresighted as solution to various biomedical difficulties 
due to distinct features like nanometric size, well-defined structure, narrow polydispersity and 
large number of surface groups. However, owing their toxic potential including hemolytic 
toxicity, cytotoxicity, immunogenicity and in vivo toxicity, the credentials of their clinical 
applications is limited. The toxicity of dendrimers is related to surface charge, generation and 
6size [17, 18]. Various approaches are being utilized to improve the therapeutic index of 
dendrimers including development of biodegradable and/or biocompatible, surface engineered 
dendrimers and use of dual drug delivery systems. The biodegradable dendrimers, generally 
composed by biodegradable repeat units that will eliminate metabolic pathways and thus will not 
accumulate, therefore considered as non-toxic [19]. Surface engineering masks the cationic 
charge of dendrimer surface either by neutralization of charge, for example PEGylation, 
acetylation, carbohydrate and peptide conjugation; or by introducing negative charge on the 
surface of dendrimers [10]. Dendrimer based hybrid nanocarrier is recognized as a recent 
approach to minimize the toxicity, improving dispersibility, biocompatibility, payloads and 
pharmacokinetics of dendrimers as compared to other carriers such as liposomes, nanoparticles, 
quantum-dots, carbon nanotubes and microsphere [20].
2.3 Dendrimer based drug targeting approach 
Dendrimers has emerged as unique polymeric globular nanoparticulate drug delivery 
system that could be judiciously utilized to tackle the deadliest disease cancer. The inimitable 
topographical molecular architect encompassing this class of delivery system could allow the 
delivery of varying nature of anticancer bioactives viz lipophilic or hydrophilic drugs and 
macromolecules as proteins or RNA. The prospect of multifunctionality owing to multivalency, 
leads to decoration of their surface by different moieties for varying function to achieve a 
common goal and this could significantly enhance the efficacy of the transported bioactives. The 
conventional chemotherapy for cancer management exhibits a lack of selectivity and thus 
affecting healthy tissues. To realize selectivity, the dendrimers could be functionalized using 
moieties that would synergistically act to target the tumoral cells and release the payloads at the 
desired site. The approach of “cellular or secondary targeting” based on moieties that leads to 
7ligand–receptor-mediated endocytosis or of “tertiary targeting” based on moieties that recognize 
internal organelles or the use of stimuli-responsive moieties that are responsible for release of 
bioactives under specific internal or external stimuli, in combination onto a single dendritic 
structure synergistically act to achieve selective targeting [3,9,20].
3. Dendrimer-based multifunctional theranostics for cancer treatment
The unique features encompassing dendrimers enable their utilization for varied 
biomedical applications. Early prognosis of the fundamental molecular processes that cause 
cancer is anticipated from modern imaging technologies. However, the conventionally used 
contrast agents suffer with short imaging time, renal toxicity and lack of specificity. Dendrimers 
are now being explored as a platform for surface conjugation of various contrast agents including 
fluorescent dyes, iodinated contrast agents, and gadolinium (Gd) or radionuclide chelators and 
for entrapment, stabilization, or assembly of metal (e.g., Au), metal sulfides, and magnetic iron 
oxide NPs, leading to the formation of a range of contrast agents for different techniques 
including single mode fluorescence, computed tomography (CT), magnetic resonance (MR), 
positron emission tomography (PET), and single photon emission computed tomography 
(SPECT), and dual mode MR/CT, MR/fluorescence, PET/fluorescence, and 
SPECT/fluorescence. Further, the scope of incorporation of drug into ligand attached dendrimer-
based contrast agents could pave the path to design dendrimer-based multifunctional theranostic 
agents for specific diagnosis and therapy of cancer [21-24]. 
Though, chemotherapy is currently considered to be the mainstream therapy for cancer 
management, however due to lack of selective targeting, it would affect healthy cells along with 
cancerous cells. Tumor physiology allows passive tumor targeting of drug-dendrimer conjugate 
by enhanced permeability and retention (EPR) effect [25]. In addition to this, molecularly active 
8targeted delivery of anticancer drugs on specific molecular target, could be achieved by surface 
functionalization of the dendrimer using various targeting moieties [26]. However, despite 
considerable efforts towards drug targeting, optimum outcome has not been observed and this 
may be due to a poor drug internalization and/or inefficient release of drug intracellularly. 
Efficient therapeutic strategy that could improve targeting and control drug release is currently 
the area of research in oncology domain. Thus, an efficient targeted drug delivery system should 
not only be able to achieve preferential accumulation and selective binding to the targeted cells 
but also been able to endorse cellular internalization, endosomal escape and control drug release 
[27, 28]. 
In view of the above, along with targeting ligand, dendritic system encompasses stimuli-
responsive controlled release function that is responsive under specific internal or external 
stimuli. Alike the feasibility of passive targeting to tumor due to EPR effect, the release of the 
drug at target site could be controlled by exploiting the differential conditions existed at tumor 
microenvironment. Presence of biochemical gradient between tumor tissue and normal 
physiological tissue such as pH, redox potential, and enzymes can be exploited as internal stimuli 
for controlling the release of drugs. Among the external stimuli, use of feature that are 
responsive to temperature and light are attached onto dendrimers to create externally triggerable 
systems [29, 30]. 
Low pH at the extracellular space of solid tumors due to excessive accumulation of lactic 
acid and lower pH of some intracellular compartments such as the endosomes and lysosomes has 
driven interest in pH responsive assemblies for cancer therapy. Likewise, interest in redox 
sensitive carrier develops due to differences in the redox potential between extracellular space 
and the cytoplasm due to accumulation of reactive oxygen species (ROS) in cancer tissue. 
9Further, overexpression of various enzymes is observed in cancerous tissue due to augmented 
metabolic processes and thus could be used for designing enzyme responsive assemblies. 
Though, the utilization of external stimuli responsive assemblies like light and temperature 
responsive moieties are being researched for cancer drug delivery, however their utilization is 
associated with concerns regarding safety and penetration depth [31, 32].
The use of stimuli responsive smart linkers between drug and dendrimer is commonly 
utilized to control the release of free drug from drug-linker-dendrimer conjugate. The release of 
the drug in response to the stimuli is due to either reversible and irreversible transformations in 
the conjugate. However most of the stimuli leads to irreversible cleavage of the linkers. 
However, the stability and liability of the bond between the dendrimer, linker and drug under 
physiological conditions and in tumor tissue respectively governs the release behavior of the 
drug from drug dendrimer conjugate [33].
In addition to this, self-assembled dendritic systems that could disassembled in response 
to stimuli could also be employed to control dug release. Noncovalent interactions such as 
hydrogen bonding, π-π stacking and hydrophobic interactions are involved in self-assembly of 
dendritic systems [34]. The stability and nature of the aggregates are dependent on hydrophilic-
hydrophobic proportion, and on external conditions  such  as  temperature and concentration [35, 
36].
Further, the class of self-immolative dendrimers is employed to control drug release 
which upon exposure to a specific trigger allow continuous degradation of their structure into 
small molecules [37]. In design, self-immolative dendrimers consists of a triggering unit 
connected to the branched skeleton composed of adaptor units. The adapter units are further 
attached with drugs as tail units. For controlled release of drugs, stimulation of trigger unit, 
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initiates rapid disassembly of the branched skeleton, with the subsequent release of all tail-units. 
“Dendritic amplification” or “Cascade-release” are the term used synonymously for the 
triggering response that leads to degradation of the conjugate [38-40]. Further, different self-
immolative bonds can be used to adjust the degradation rate of the conjugate [41].
This review highlights various stimuli responsive dendritic assemblies utilized for the 
delivery of anticancer drugs. Different types of internal and external stimuli including acid, 
reduction potential, enzyme, temperature and light are discussed along with the respective 
responsive linkers that trigger the release in response to stimuli. 
4. pH responsive dendrimers 
The existence of pH gradient between tumor microenvironment (pH ~6.5) and normal 
tissues (pH ~7.4) act as a trigger for the controlled release of payloads from the drug delivery 
systems. An acid responsive functionality is anchored with such delivery devices, which remains 
stable in neutral and alkaline environment but gets degraded or hydrolyzed on exposure to acidic 
environment to release the drug. Further, some intracellular compartments, such as the 
endosomes and lysosomes have an acidic pH profile (4.5–6.5) that could trigger cytoplasmic 
drug release from acidic endo-lysosomal compartments [42]. 
Rapid proliferation effect in tumor tissues results in enhanced glycolysis instead of 
oxidative phosphorylation resulting in excessive accumulation of lactic acid and this will lead to 
slight decrease in pH of tumor extracellular environment. This decrease in pH is first observed 
by Warburg and is termed as Warburg effect [43, 44]. 
Presence of ionizable functional groups such as amine and carboxylic acid on surface or 
inner of dendrimer exhibit a pH-dependent release due to disruption of amphiphilicity of the 
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system. For example, low pH leads to protonation of tertiary amine which decreases the interior 
hydrophobicity of dendrimer and facilitate the release of payloads at the tumor site [45-47]. 
The pH gradient, also driven disassembly of assemble structure of amphiphilic 
dendrimers and thus aid in controlling release of payloads. Under specific pH conditions 
amphiphilic dendrimers assembled into micelles and these assembled structures tend to 
disassemble with altered conformation due to pH driven alteration in hydrophilic-lipophilic 
balance (HLB) [48, 49].
4.1 pH responsive linkers
The use of acid labile linkers could also be utilized in the construction of pH sensitive 
dendrimer. The acid labile linkers respond to variation in pH, they remain stable in neutral or 
alkaline pH, but degraded or hydrolyzed at acidic pH. Among pH-responsive linkers, the most 
frequently employed for anticancer drug delivery via dendrimer drug conjugate are hydrazone, 
acetal, and cis-acotinyl (Table 1) [42, 50].
4.1.1 Hydrazone linkage
Hydrazone linkages are most commonly used pH responsive linkage for designing 
dendrimer-prodrugs for cancer therapy. The hydrazone linkages hydrolyzed under acidic 
conditions and remain stable at neutral and alkaline pH [51]. The most common synthetic 
pathway for hydrazone is the condensation between hydrazines and ketones or aldehydes. 
Though hydrazones could also be synthesized by reaction between aryl halides and non-
substituted hydrazones, and by reaction between aryl diazonium salts and beta-keto esters or 
acids (Japp-Klingemann reaction) [52].
A ketone or aldehyde group is required for hydrazone formation and thus hydrazine 
linkage is common with Doxorubicin (DOX)-dendrimer prodrug (Figure 1). Antitumor drugs, 
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without this functional group requires additional modification for conjugation via hydrazone 
bond. Drugs bearing hydroxyl group such as Paclitaxel (PTX), docetaxel (DTX) and cis-platin 
could be esterified with acid anhydride or carboxylic acid to obtain active keto sites for 
hydrazone formation.
Cheng et al, observed the pH-dependent release of DOX by formulating folic acid 
conjugated poly(ethylene glycol) (PEG)5000-PAMAM(G4) dendrimers using hydrazine linkers. 
In vitro release of DOX from PAMAM-DOX conjugate was evaluated at pH 4.5, 5.5 and 7.4, 
which was found to be 42, 28 and 8%, respectively. The results revealed the stability of 
hydrazine linker at pH 7.4 and lability at acidic pH [53]. In another report an amphiphilic linear-
dendritic prodrug (mPEG-PAMAM-DOX) for the co-delivery of 10-hydroxy-camptothecin 
(HCPT) and DOX using acid-labile hydrazine linker was design and revealed acid responsive 
release behavior. It was observed that as the pH is decrease by 7.4 to 4.5 the release is increased 
from 5 to 60% revealing pH dependent cleavage of hydrazone linkage [54]. Likewise, She et al, 
designed mPEGylated peptide dendron-DOX (dendron-DOX) conjugate and demonstrated pH-
dependent release of DOX using hydrazone linkage. The in vitro release revealed 20 and 80% 
drug release at pH 7.4 and 5, respectively [55]. Same research group also observed the release of 
DOX from galactose functionalized PEGylated dendrimer-DOX conjugates having hydrazone 
linkage. Due to cleavage of pH sensitive hydrazone linker, the release of DOX from the 
conjugates at pH 5 was much rapid than those at pH 7.4 [56]. 
Hydrazone linkage was successfully employed for conjugation of DOX to pH-sensitive 
drug-dendrimer conjugate-hybridized gold nanorods (PEG-DOX-PAMAM-AuNR). Drug release 
studies revealed that the release of DOX from the conjugate was negligible at pH 7.4, but was 
boosted considerably at weak acidic pH [57].
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A biodegradable hyper-branched HPMA copolymer-DOX conjugate was synthesized 
with cathepsin B sensitive peptide GFLGK and the anticancer drug DOX was attached to the 
branched copolymer via a pH-responsive hydrazone bond. As compared to traditional 
copolymers, the biodegradable multiblock HPMA copolymer-drug conjugates resulted in 
enhanced anticancer efficacy with no obvious side effects [58]. 
4.1.2 Acetal linker
Chemically an acetal is an organic molecule having a central carbon atom attached to two 
oxygen atoms by single bond. For ketone derivatives, they are called ketals and are commonly 
used as protecting groups in organic synthesis and for the design of acid-sensitive linkages [59]. 
Acetal linkages can be formed by reaction between an aldehyde or ketone and alcohol [60] or 
between alcohol or phenols and vinyl ether, in the presence of acid catalysts [61]. Acetals are not 
stable to acidic environment and are very readily hydrolyzed back to the carbonyl and alcohol. 
However, there are only a few reports of application of acetals as pH-sensitive linkers for 
anticancer drug delivery using dendritic system. 
The pH-responsive micelles based on PEO-dendritic polyester copolymer anchoring an 
anticancer drug, DOX by acid-labile acetal groups demonstrated the hydrolysis of acetal groups 
at acidic pH. The DOX was selectively released in tumor vicinity including endosomes and 
lysosomes [62].
4.1.3 Cis-acotinyl linker
The cis-aconityl, a derivate of natural aconitic acid is commonly used for controlling the 
release of amine group containing drugs. The interaction between cis-aconitic anhydride and an 
amine drug leads to a ring opening, which has a carboxylic functionality for conjugating to 
dendrimer. In mildly acidic conditions, the amide bond undergoes hydrolysis to release the drug. 
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In an interesting study Yabbarov et al, formulated a conjugate comprising rAFP3D 
(alpha-fetoprotein) acting as targeting ligand, PAMAM G2 dendrimer and DOX. The cis-
aconityl linkage was used to conjugate DOX with PAMAM G2 dendrimer. The in vitro release 
study demonstrated that the release of DOX was found to be pH dependent with 8, 75 and 90% 
drug release at pH 7.4, 6.0 and 5.5, respectively [63]. Zhong and Da Rocha synthesized 
PEGylated G3 PAMAM-DOX conjugate by using an acid labile (cis-aconityl) and acid non-
labile (succinic) linker. In vitro release studies conducted at pH 7.4 and 4.5 revealed 9 and 85% 
DOX release, respectively [64]. 
Similarly, Zhu et al, synthesized PEGylated PAMAM G4 dendrimers with different 
degrees of PEGylation and conjugated with variable amounts of DOX through cis-aconityl and 
succinic linker and term as PPCD and PPSD prodrugs, respectively. The in vitro release study 
showed negligible amounts of drug released from PPSD prodrug at varied pH values and pH 
dependent drug release from PPCD prodrug. The cytotoxicity study on murine B16 melanoma 
cells reveals significant toxicity by PPCD prodrug and negligible toxicity by PPSD prodrug [65].
4.1.4 Boronate ester linkers
Reaction between boronic acid and 1,2-diol or 1,3-diol in aqueous medium leads to the 
formation of boronate ester, a covalent ester bond. The bond is stable at pH higher than its pKa 
value but unstable at pH lower than its pKa value. Therefore, boronate ester can be used as pH 
sensitive linker to construct pH responsive assemblies [66, 67]. 
Boronate ester bond can be used to prepare bortezomib prodrugs. Catechol-modified 
PAMAM dendrimer was conjugated to an anticancer drug, Bortezomib via the boronate ester 
bond. The results revealed the drug release in acidic environment (pH 6.5) and no release at 
physiological pH [68].
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4.1.5 N, O-chelate linker
A pH-responsive mPEGylated peptide dendrimer-linked diaminocyclohexyl platinum (II) 
(dendrimer-DACHPt) conjugate was prepared by Pan et. al. The DACHPt has a molecular 
structure, is and activity closely related to oxaliplatin. To achieve pH-sensitive DACHPt 
conjugation, the N,O-chelate was utilized to link the DACHPt to the dendrimers. The conjugate 
was pH-responsive and released drug significantly faster in acidic environments (pH 5.0) than 
pH 7.4. The result revealed that the conjugates suppressed tumor growth better than clinical 
oxaliplatin without inducing toxicity in an SKOV-3 human ovarian cancer xenograft [69].
5. Redox-responsive dendrimers
Control over release of drug in response to difference in the reduction potential between 
tumors and normal tissue is frequently employed strategy in cancer therapy. There is highly 
regulated redox status inside the normal cell balancing the reduced and oxidized species. This 
balance gets disturbed in cancerous cells, which leads to accumulation of ROS and results in 
oxidative stress. To overcome oxidative stress, cells recruit ROS scavengers such as glutathione 
(GSH) and vitamins C and E. The significant difference (about 4-fold) in GSH concentration 
intracellularly (2-10×10-3 M) and extracellularly (2-20 µM) in cancerous tissue have made GSH 
responsive assemblies most explored for reductive responsive drug delivery systems [70-72]. 
Further, a specific reducing enzyme, gamma-interferon-inducible lysosomal thiol reductase 
(GILT) modulates the redox potential of endosomal compartment in the co-presence of a 
reducing agent such as cysteine [73-75].
The frequently used redox-reponsive linker for dendrimer drug conjugate is disulphide 
linker. The elevated GSH mediates disulfide bond cleavage reactions via reduction or dithiol-
disulfide exchange process (Figure 2). Besides disulfide bonds, diselenide or ditellurium bonds 
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are also used as redox responsive linkers. The diselenide bond is more sensitive than disulphide 
bond towards stimuli as the cleavage energy of diselenide bonds is lesser as compared to 
disulfide bonds [76-78].
A novel stimulus responsive conjugate of dendrimer and gold nanoparticle (GNP) was 
developed for the delivery thiolated anticancer drugs by Wang et al. Dendrimer-encapsulated 
gold nanoparticles (DEGNPs) were synthesized and thiolated anticancer drugs are attached 
through the Au-S linkage. The conjugate exhibited an “Off-On” release behavior in the presence 
of thiol-reducing agents such as glutathione and dithiothreitol. The developed conjugate showed 
much reduced cytotoxicity as compared to the free anticancer compounds [79]. 
A new class of disulfide cross-linked G2 PAMAM dendrimers was prepared as non-viral 
gene carrier to enhance transfection efficacy and to reduce cytotoxicity. Disulfide containing 
linker 3,3′-dithiodipropionicacid-di(N-succinimidyl ester), (DSP) was used to cross-link G2 
PAMAM dendrimers to form supra-molecular structures (G2DSPs). The cross-linked conjugate 
was degraded due to disulfide bond reduction after gene transfection and this regulated the 
release of DNA in a controlled manner [80].
In a recent study a redox responsive peptide conjugated tumor targeted nano vehicle 
(PSPGP) composed of branched PEG with G2 dendrimers was synthesized for co-delivery of 
PTX and siTR3 for treatment of pancreatic cancer. The assembly was conjugated with PTP 
(plectin-1 targeted peptide, NH2-KTLLPTP-COOH), a biomarker for pancreatic cancer. Redox-
responsive disulfide bonds were used to link the PTX and siTR3 to the conjugate. The complex 
showed inhibition in tumor growth and promoted cancer cell apoptosis [81]. 
Lim et al, synthesized 3 conjugates of PTX with PEGylated triazine dendrimer. The 
dendrimer construct 1 includes an ester linker, whereas dendrimer construct 2 and 3 include a 
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disulfide linker. Cytotoxicity studies using an MTT-based assay and PC-3 cells revealed IC50 
values of 4.5 and 29 nM for free PTX and construct 1, respectively and increased in construct 2 
and 3 from 74 to 26 nM and 13nM in the presence of 1 mM glutathione and 1 mM dithiothreitol, 
respectively [82]. 
Reduction-responsive amphiphilic dendritic copolymer (TPP-S-S-G3) with disulfide-
linkages between dendrimer (PEG-G3-OH) and porphyrin (TPP, photosensitizers) for the 
combined chemotherapy and photodynamic therapy (PDT) was developed. The copolymer self-
assembled into micelles in aqueous solution. The results showed fast uptake and release of DOX-
loaded TPP-S-S-G3 micelles by MCF-7 cells [83]. Nguyen et al, studied Heparin (Hep) 
conjugated to PAMAM G3.5 (P) via redox-sensitive disulfide bond (P-SS-Hep). The dendrimer 
complexes were found to promote redox-sensitive drug release intracellularly. In the cancer cells 
the disulfide linkage cleaved and enabled the release of drug. Hence, providing evidence of 
potential of redox sensitive nanocarriers in cancer chemotherapy [84]. 
Dual responsive PAMAM dendrimers that responded to variation in reduction potential 
and pH have been used for the delivery of DOX. The redox-responsive functionality is imparted 
using disulfide linkage between PAMAM dendrimers and PEG with DOX loaded into the 
hydrophobic core of the conjugates. The release study demonstrated redox and acid trigger 
release behavior of DOX [85]. For tumor-targeted drug delivery an asymmetric bow-tie 
PAMAM dendrimer (ABTD) scaffold has been developed using disulfide unit as self-immolative 
linker. The results revealed a remarkable selectivity of ABTD scaffold to cancer cells as 
compared to human normal cells and demonstrated reduction responsive release behavior [86]. 
A GSH-triggered self-immolative dendritic prodrug has been designed for cancer 
therapy. The assembly comprised an anticancer drug Camptothecin (CPT), a reduction cleavable 
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linker (2,4-dinitrobenzenesulfonyl, DNS) and a near infrared (NIR) fluorescent dye 
(dicyanomethylene-4H-pyran, DCM). Cleavage of the DNS linker in the presence of GSH 
released the drug and activated NIR fluorophore, which could aid to track the released drug [87].
To develop highly efficient and safe gadolinium (Gd)-based MRI contrast agents with 
minimum bio-accumulation and least detrimental effect on the body, Guo et.al, develop 
biodegradable Gd-based polymeric contrast agents with a biocleavable disulfide linker. 
Biodegradable poly[N-(1,3-dihydroxyprpyl) methacrylamide] copolymers (pDHPMA) were 
synthesized and small molecular Gd-chelate (Gd-DOTA) was conjugated onto the copolymer 
backbone through a sulfide bond or a GSH-sensitive cleavable disulfide bond to produce two 
novel Gd-mCAs (pDHPMA-Cy5.5-DOTA-Gd or pDHPMA-Cy5.5-SS-DOTA-Gd) for tumor 
diagnosis. The developed contrast agents demonstrated enhanced relaxation efficiency, improved 
pharmacokinetics and better passive targeting through EPR effect as compared to Gd-
diethylenetriamine pentaacetic acid (DTPA-Gd) [88].
6. Enzyme-responsive dendrimers
Changes in the level and activity of various enzymes are observed in cancer etiology. As, 
cellular metabolic processes are augmented in cancer tissue, the enzymes that regulate these 
processes are commonly overexpressed. This dysregulation of their expression is considered as 
characteristic feature of the cancer and is utilized as a tool in diagnostics. Along with 
diagnostics, such dysregulation is utilized in managing the disease condition by programming the 
drug delivery system for active targeting and to control the release of drugs. The on-demand drug 
release, governed by enzyme is designed by integrating specific linkers that can be recognized 
and degraded by the enzymes overexpressed in the extracellular or intracellular environment of 
the tumor [89, 90]. A variety of enzymes are found to be upregulated in tumor tissues including 
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cathepsins, matrix metalloproteases (MMPs), hyaluronidase, azoreductase, phospholipase and 
many more [91].
Further, the advent of enzyme responsive self-immolative dendrimers as molecular 
amplifiers has translated the release of drug on enzymatic stimulation. Incorporation of drug 
molecules as the tail units and an enzyme substrate as the trigger in self-immolative dendrimers, 
generated a prodrug unit that was triggered upon a single enzymatic cleavage. The enzymatic 
trigger commonly utilized for the same is 38C2 antibody, penicillin-G-amidase and β-
galactosidase [92, 93].
Cathepsins, a group of proteolytic enzymes predominantly located in endo/lysosomal 
vesicles, are involved in the degradation of extracellular matrixes (ECM) of the tumor tissue and 
thus contributing to infiltration of the tumor cell. Out of various cathepsins, cathepsin B is one of 
most explored lysosomal proteases due to its high expression in various types of cancers 
including prostate, breast, lung, brain, endometrium and colorectum. Invasive and metastatic 
cancers are the results of abnormal regulation of cathepsins [94, 95]. 
Lee et al, synthesized dendrimer-methoxy PEG (MPEG)-DOX conjugates using a 
cathepsin B-cleavable peptide, glycyl phenylalanyl leucyl glycine tetra-peptide (Gly-Phe-Leu-
Gly) for anticancer drug targeting (Figure 3). The results revealed improved anticancer activity 
in an in vivo CT26 tumor xenograft model i.e. the volume of the CT26 tumor xenograft was 
significantly inhibited [96]. 
Cathepsin B-cleavable peptide (Gly-Phe-Leu-Gly) was successfully used to develop a 
novel enzyme-responsive PEGylated lysine peptide dendrimer-gemcitabine (GEM) conjugate 
(Dendrimer-GEM) based nanoparticle. The results indicated suppressed relative tumor volumes 
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(86.17±38.27%) and a 2-fold higher value of tumor growth inhibition (∼90%) than GEM, 
establishing enhanced antitumor efficacy without obvious systemic toxicity [97].
In another study cathepsin B-cleavable peptide was utilized by Zhang and coworkers to 
develop mPEGylated peptide dendrimer-DOX (dendrimer-DOX) conjugate-based nanoparticles, 
which demonstrated significantly high antitumor activity and substantially reduced DOX-related 
toxicities [98]. Similar peptide along with a pH-sensitive hydrazone bond was exploited by Chen 
et al, for the preparation of a novel pH/enzyme sensitive dendritic polymer-DOX conjugate for 
cancer treatment. The result revealed high accumulation of DOX into tumors due to prolonged 
blood circulation time. In vivo studies revealed better antitumor efficacy of the conjugate in 
comparison with free DOX [99].
Wang et al, designed an enzyme-stimuli nanogel based on G4 PAMAM dendrimers using 
elastase cleavable bond (Ac-arg-ala-ala-asp-D-tyr-cys-NH2) (RAADyC). Neutrophil elastase 
(NE) is detected in different types of cancers, and its concentration is associated with the cancer 
stage, grade, and the survival [100].
Azoreductase, an enzyme over-expressed in hepatocellular carcinoma cells, can work as a 
trigger to induce drug release. Medina et al, synthesized a series of aromatic azo-linkers (L1-L4), 
which were used to conjugate DOX to G5 PAMAM dendrimers. To study the effect of 
electronegativity on susceptibility to cleavage by azoreductase enzymes, these linkers are 
incorporated with electron-donating oxygen (O) or nitrogen (N) groups. Results revealed the 
release of 4-8, 17, 60, and 100% of the conjugated DOX molecule from dendrimers having 
linkers L1 to L4, respectively. Increase in electronegativity increases susceptibility to cleavage 
by azoreductase enzymes [101].
21
Phospholipase C (PLC) enzyme, an important regulator of membrane phospholipid 
metabolism is found to be overexpressed in many cancers and participates in cancer cell 
progression and differentiation [102,103]. Zhang et al, synthesized enzyme-responsive 
phosphoramidate (PAD) dendrimers for delivery of DOX. The dendrimers were degradable in 
the presence of PLC but found to be stable in phosphate buffer saline (PBS). The phosphite ester 
bonds in PAD dendrimers is degraded by PLC. The results revealed improved therapeutic 
efficacy of the conjugate with reduced toxicity in athymic nude mice bearing xenografts of 
MCF-7/ADR breast cancer [104].
A dendritic prodrug with an anticancer agent camptothecin (CPT) and a trigger that 
allowed activation by penicillin-G-amidase was designed and synthesized. Cell-growth inhibition 
assays demonstrated that the toxicity of the dendritic prodrug was found to be dependent upon 
incubation with penicillin-G-amidase [105]. Shamis et al, prepared a self-immolative assembly 
for synergistic combinational therapy in cancer utilizing DOX and CPT as tail units and a 
catalytic antibody 38C2 cleavable retro-aldol retro-Michael focal trigger [106]. 
In an effort to improve therapeutic index of an anti-cancer drug, gemcitabine (GEM), a 
stimuli-responsive dendritic polyHPMA copolymer was designed and synthesized GEM 
(Dendritic polyHPMA-GEM) prodrug via one-pot synthesis of RAFT polymerization by Dai and 
coworkers. GEM was conjugated onto the dendritic polymeric carrier via an enzyme-responsive 
linker glycyl-phenylalanylleucyl-glycine tetra-peptide (GFLG), which was found to be stable in 
blood circulation system and degraded in the presence of Cathepsin B only. The results revealed 
that the designed stimulus-responsive dendritic copolymer-GEM prodrug may a safe, effective 
and enzyme-responsive anticancer agent [107].
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 Polymer-drug conjugates has significantly improved the anti-tumor efficacy of 
chemotherapeutic drugs and alleviated their side effects. In this regard a biodegradable diblock 
N-(1,3-dihydroxypropan-2-yl) methacrylamide (DHPMA) copolymer-DOX conjugate (a self-
aggregation-induced nanoprodrug) via one-pot of RAFT polymerization and conjugate chemistry 
was developed. Notably, the nanoprodrug had a significantly prolonged blood circulation time 
with an elimination half time of 9.8 h. It displayed high accumulation within tumors, and 
improved e in vivo therapeutic efficacy against 4T1 xenograft tumors compared to free DOX. 
The authors demonstrated that the diblock pDHPMA-DOX nanoprodrug with a controlled 
molecular structure exhibited an enhanced antitumor efficacy against 4T1 breast tumors through 
the inhibition of cell proliferation and antiangiogenic effects and alleviated side effects, showing 
a great potential as an efficient and safe anticancer agent [108].
7. Temperature-responsive dendrimers
Among external stimuli, temperature trigger drug release has shown significant potential. 
However, the use of temperature as a trigger requires external heating methodology that can heat 
the tumor area locally and thus respond to temperature variation [109]. Modification of 
dendrimer surfaces with oligo- and poly-ethylene oxide-based functionality endow them with 
temperature-sensitive characteristics [110]. 
There is an inverse relationship between aqueous solubility and temperature for 
temperature sensitivity functionalities. As temperature is increased the degree of hydrogen 
bonding between the temperature sensitive moieties and water decreases, and this will leads to 
phase separation. Lower critical solution temperature (LCST) or the cloud point is the phrase 
used demark such phase transition and is specific for a moiety [111]. Most commonly used 
thermo-responsive material includes PEG and poly(N-isopropylacrylamide) (pNIPAM). These 
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functional groups become hydrated due to hydrogen bonding with water and the application of 
temperature trigger breakdown of these weak interactions causing them to lose its hydrophilicity 
[112,113].
Thermosensitive pNIPAM polymer-conjugated PAMAM dendrimer has efficiently 
delivered Malloapelta B (Mall B) against HepG2 cancer cell proliferation. The conjugate showed 
high encapsulation of Mall B and demonstrated slow controlled release, which significantly 
inhibited HepG2 cancer cell proliferation [114]. Wu et al, synthesized G4 thermosensitive 
dendrimers based on oligo (ethylene glycol) (OEG) conjugated with an antitumor agent, GEM. 
The prepared dendrimers were compared with that of GEM-conjugated PAMAM dendrimers. 
The GEM-OEG based dendrimers exhibited thermal responsive release behavior and better 
tumor accumulation and penetration than the GEM-conjugated PAMAM [115]. 
A temperature responsive dendrimer conjugate was prepared for gene silencing through 
intracellular small interfering RNA (siRNA) release. The pNIPAM and phenylboronic acid were 
conjugated with PAMAM dendrimer for the design temperature responsive system. The 
phenylboronic acid improves the stability and cellular uptake while pNIPAM is responsible for 
temperature responsive behaviors at lower critical solution temperature. The results revealed that 
gene silencing efficacy was significantly increased by cool treatment after its cellular uptake 
with minimal toxicity [116].
Though, temperature-sensitive materials for dendrimer drug conjugate is numerous, a few 
are potentially utilized for temperature-responsive drug release. This is probably due to difficulty 
in controlling the release of the drug during phase transition and the safety concerns of the 
temperature-sensitive polymers above LCST for in vivo applications. Further, it is very difficult 
to heat localized tissues without hurting normal tissues. 
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8. Light-responsive dendrimers
As external stimuli, light is most explored due to some obvious advantages such as non- 
invasiveness and prospect of temporal and spatial accuracy. The principle governing the release 
of drug from dendrimers using light as a stimulus is based on- (i) the absorption of light by 
photosensitive ligands that would trigger reversible physical changes (e.g., trans-cis 
isomerization) and cause release of the encapsulated drugs and (ii) the absorption of light by 
photosensitive ligands causes irreversible cleavage reaction. The most common photosensitive 
ligands for the former are azobenzene derivatives and for later are o-nitrobenzyl ether (or ester) 
derivatives grafted on the surface of dendrimers [117].
The commonly used light triggers includes ultraviolet (UV) (200-400 nm), visible (400-
700 nm) or near-infrared (NIR) (700-1000 nm) light. However, UV and visible light usage gives 
poor tissue penetration as well as leads to phototoxicity. NIR light irradiation has deeper tissue 
penetration with the penetration depth of up to 2 cm with less phototoxicity and thus preferred. 
Nevertheless, NIR light has inherent low energy and due to this two-photon excitation technique 
would be considered ideal for photobiological applications using NIR light irradiation or the 
application of upconversion nanoparticles, which can convert adsorbed NIR light to UV 
irradiation (Figure 4) [118-120].
Choi et al, designed folic acid conjugated G5 PAMAM dendrimer and photocaged DOX 
using the photocleavable group ortho-nitrobenzyl (ONB) (Figure 5). The in vitro cytotoxicity 
studies using KB cell-based assay revealed release of DOX and cytotoxicity on exposure to UV 
light [121]. Similarly, in another study same group of researchers designed targeted PAMAM 
dendrimer for the delivery of methotrexate (MTX). The in vitro cytotoxicity study using KB cell-
based assay demonstrated MTX release through a light-controlled mechanism following 
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exposure to UV light [122]. Sun et al, designed DOX loaded Janus-type dendritic structure by 
linking a hydrophobic dendron (diazonaphthoquinone (DNQ)-decorated G3 PAMAM) and a 
hydrophilic dendron (lactose (Lac)-decorated Gm PAMAM dendrons). The DNQ, undergoes a 
Wolff rearrangement to form a ketene, on exposure to light. These Janus dendritic structure gets 
self-assembled into micelle in aqueous solution and gets disassemble on exposure to NIR light. 
The results presented a photo-triggered cytotoxicity and revealed doubling of DOX release on 
irradiation to NIR [123].
Coumarin, a natural dye, with high two-photon cross sections is utilized as photocages 
for the light responsive release of chemotherapeutic drugs [124]. Wang et al, synthesized a light 
responsive construct for the co-delivery of 5-Flurouracil (5-Fu) TRAIL plasmid for cancer 
therapy. The anticancer moieties were loaded on amphiphilic G1 dendrimer-coumarin conjugate 
(G1-CM). Coumarin acts as photoresponsive group and on exposure to light leads to degradation 
of the assembled structure and exhibits a light-responsive drug release profile [125].
Thioacetal ortho-nitrobenzaldehyde TNB(OH) photolinker was utilized for the 
construction of TNB-caged DOX conjugates. The constructed caged conjugates are then 
integrated with 2 folic acid functionalized nano-assemblies. First is, G5 PAMAM dendrimer and 
second is upconversion nanocrystal (UCN) conjugate with protoporphyrin IX (PPIX) as 
cytotoxic photosensitizer. Cellular toxicity studies in KB carcinoma cells revealed that each 
nano-assembly exhibit cytotoxicity on exposure to UV or NIR (980 nm) [126]. However, despite 
various obvious benefits of light as a stimulus for drug release, its application is limited in the 
treatment of solid tumor due to the ambiguity regarding penetration depth, irradiation time and 
effective area.
9. Smart dendrimers in gene delivery
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An alternative strategy to traditional radiotherapy and chemotherapy, gene therapy is now 
recognized as a potential therapeutic modality for cancer treatment. Gene therapy has been 
extensively explored for the management of cancer, as approximately 65% of the clinical trials in 
gene therapy have been designed at the treatment of various types of cancers [127]. To realize 
gene transfer complex cellular and tissue barriers must be overcome without disrupting vital 
regulatory mechanisms to deliver the tailored therapeutic gene for augmentation or suppression 
or repair, using a vehicle called vector [128]. 
In addition to carrier of chemotherapeutic agent and contrast agent in molecular imaging 
for cancer treatment and prognosis, dendrimers are also considered as non-viral vector for gene 
therapy. In contrast to viral vectors, dendrimers as a non-viral vector offer distinct advantage 
including target-cell specificity and resistance to repeated administration. Further, the 
biodegradable dendrimers are preferred for gene delivery as compared to the non-degradable 
dendritic vectors, due to their reduced toxicity and degradability. The PAMAM dendrimers, 
dendritic polyglycerols and peptide dendritic polymers are the commonly investigated vectors 
for gene therapy [129, 130]. 
Alternatives to viral-mediated gene delivery, dendrimers are now being largely 
investigated as an effective non-viral mediated gene delivery system. Though, viral vectors have 
high transfection efficacy but are accompanied by high immunogenicity, cytotoxicity and 
production problems. Owing to possibility of multifunctionality, dendrimers are perceived as 
non-viral vector that can overcome these limitations [131]. However, cationic dendrimers is 
associated with serious toxicity and thus a key challenge in clinical gene therapy is to prepare 
dendritic vector with high transfection efficacy and low toxicity. Fluorinated dendrimer, a new 
class of non-viral gene carriers exhibits interesting physicochemical properties, with efficient 
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cellular internalization and less toxicity [132,133]. A structure-activity relationships (SAR) study 
for DNA and siRNA delivery based on different dendrimer generations and fluorination degrees 
reveals that fluorination significantly improves the transfection efficacy of G4-G7 PAMAM 
dendrimers. Fluorination on G5 dendrimer yields the most efficient polymers in gene delivery, 
and the transfection efficacy of fluorinated dendrimers depends on fluorination degree. All the 
fluorinated dendrimers cause minimal toxicity on the transfected cells at their optimal 
transfection conditions [134].
A series of fluorodendrimers was synthesized, by reacting PAMAM dendrimers with 
heptafluorobutyric anhydride, as non-viral gene vectors. The synthesized conjugate self-
assembled to form uniform polyplexes with promising properties at a low nitrogen-to-
phosphorus ratio and have low charge densities and relatively weak DNA associations. Uniform 
polyplexes ensures reproducible gene transfection. A low charge density indicates low 
cytotoxicity and weak DNA association, which is beneficial for efficient DNA unpacking in the 
cytoplasm [135].
The interaction of G5 PAMAM dendrimers with perfluoro acid anhydrides resulted in the 
development of fluorinated dendrimers with high transfection efficacy and low toxicity. The 
study revealed that fluorination of the dendrimers improved the transfer across cell as well as the 
endosome/lysosome membrane facilitating endosomal escape. Further, this class of dendrimer 
has shown to form polyplexes with genes at low nitrogen to phosphorus (N/P) ratios to minimize 
the toxicity on the transfected cells [136].
A stimulus-responsive fluorinated bola-amphiphilic dendrimer bearing ROS-sensitive 
thioacetal in the hydrophobic core and positively charged PAMAM dendrimer at the terminals 
was synthesized for the delivery of siRNA in cancer cells. The conjugate combine the 
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advantageous delivery features of both lipid and dendrimer as a non-viral vector. The result 
revealed that the conjugate capable of interacting and compacting the negatively charged siRNA 
into nanoparticles to protect the siRNA and promote cellular uptake [137].
A heptafluorobutyric acid modified G4PAMAM dendrimer (G4-F735) has been used as a 
nonviral vector to deliver plasmid encoding TNF-related apoptosis-inducing ligand (pTRAIL) 
gene for cancer treatment to achieve both excellent transfection efficacy and low toxicity. The 
results revealed much higher TRAIL gene transfection efficacy than a series of transfection 
reagents including poly(ethylene imine) (PEI), SuperFect and Lipofectamine 2000 and exhibited 
minimal toxicity in vitro [138].
For the investigation of fluorous effect on transfection efficacy and cytotoxicity, Wang 
and Cheng synthesized a series of fluorobenzoic acid (FBA)-modified dendrimers as non-viral 
gene vectors. The results demonstrated that the transfection efficacy increases with increasing 
number of fluorine atoms on the aromatic rings. The modified dendrimers were found to be 
superior as compared to the polymer-based and lipid-based commercial reagents such as 
SuperFect, PolyFect, and Lipofectamine 2000, respectively. Fluorination on the aromatic rings 
significantly improves the transfection efficacy of benzoic acid-modified dendrimers [139]. 
In a study fluorodendrimer was prepared by reacting G2 PAMAM dendrimer with 
heptafluorobutyric anhydride for the co-delivery of fluorinated anticancer drugs (sorafenib or 5-
Fu) and therapeutic genes (TRAIL plasmid) in synergistic cancer therapy. The results revealed 
high drug loading and gene transfection efficacy with minimal toxicity [140]. 
10. Conclusion
The synergy that exists between experimental and theoretical studies opens new avenues for the 
use of dendrimers as versatile drug delivery systems. The possibility of diverse functionalization 
29
on dendritic structure paves the path for delivery of drugs in spatial-, temporal- and dosage-
controlled fashions for cancer therapy. The use of stimuli responsive smart linkers facilitates the 
delivery of payloads in a controlled manner on specific triggers. The incorporation of pH and 
redox responsive systems into dendrimers, has attracted significant interest. Various functional 
groups have been utilized in dendritic assemblies such that a pH sensitive linker would provide 
stability to the assembled nanostructure stable at neutral pH 7.4, but would respond to a lower 
pH. The use of pH-, redox-, enzyme-, thermal- and light-responsive ligands potentiate the target 
functionalized dendrimers in delivering anticancer bioactives in an efficient and safer manner.
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Table legend:
Table 1. Acid-responsive chemical bonds and corresponding degradation products under acidic 
environment [Modified and reproduced with permission from Ref 42]
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Fig 1. Dendrimer-doxorubicin conjugate via hydrazone linkage [Modified and reproduced, with 
permission from Ref 32]
Fig 2. Cleavage of disulfide bond between dendrimer–drug conjugates via GSH [Modified and 
reproduced, with permission from Ref 32]
Fig 3. Cleavage of glycyl phenylalanyl leucyl glycine tetra-peptide (GFLG) between dendrimer-
doxorubicin conjugates by Cathepsin-B [Modified and reproduced, with permission from Ref 32]
Fig 4. Photo-cleavable groups: (a) Ortho-nitrobenzyl (ONB) group and (b) Coumarin [Modified 
and adopted from Ref 118].
Fig 5. Cleavage of ortho-nitrobenzyl (ONB) linker in dendrimer-doxorubicin conjugate upon UV 
light irradiation [Modified and reproduced, with permission from Ref 32]
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Table 1. Acid-responsive chemical bonds and corresponding degradation products under acidic environment [Modified and reproduced with 
permission from Ref 42]
Acid-responsive 
chemical bond
Structure Degradation products Reference
Cis-Aconityl
Hydrazone
Acetal
[42]
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Fig 1. Dendrimer-doxorubicin conjugate via hydrazone linkage [Modified and reproduced, 
with permission from Ref 32]
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Fig 2. Cleavage of disulfide bond between dendrimer–drug conjugates via GSH [Modified 
and reproduced, with permission from Ref 32]
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Fig 3. Cleavage of glycyl phenylalanyl leucyl glycine tetra-peptide (GFLG) between 
dendrimer-doxorubicin conjugates by Cathepsin-B [Modified and reproduced, with 
permission from Ref 32]
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Fig 4. Photo-cleavable groups: (a) Ortho-nitrobenzyl (ONB) group and (b) Coumarin 
[Modified and adopted from Ref 118].
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Fig 5. Cleavage of ortho-nitrobenzyl (ONB) linker in dendrimer-doxorubicin conjugate upon 
UV light irradiation [Modified and reproduced, with permission from Ref 32]
